24. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. 2012.
ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American
Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology.
screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin.
62:147-172
25. Ciapponi A, Bardach A, Glujovsky D, Gibbons L, Picconi MA. 2011. Type-specific HPV
prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic
review and meta-analysis. PLoS One. 6:e25493.
26. Gage JC, Schiffman M, Solomon D, Wheeler CM, Gravitt PE, Castle PE, et al. 2013.
Risk of precancer determined by HPV genotype combinations in women with minor cytologic
abnormalities. Cancer Epidemiol Biomarkers Prev. 22:1095-1101.
27. Lee EH, Um TH, Chi HS, Hong YJ, Cha YJ. 2012. Prevalence and distribution of
human papillomavirus infection in Korean women as determined by restriction fragment mass
polymorphism assay. J Korean Med Sci. 27:1091-1097.
28. Argyri E, Papaspyridakos S, Tsimplaki E, Michala L, Myriokefalitaki E, Papassideri I, et al.
2013. A cross sectional study of HPV type prevalence according to age and cytology. BMC Infect
Dis. 13:53. doi:10.1186/1471-2334-13-53.
29. Dursun P, Ayhan A, Mutlu L, Çağlar M, Haberal A, Güngör T, et al.2013. HPV types in
Turkey: multicenter hospital based evaluation of 6388 patients in Turkish gynecologic oncology
group centers. Turk Patoloji Derg. 29:210-216.
30. Zhou H, Mody DR, Schwartz MR, Coffey DM, Smith D, Zwain OA, et al. 2014. Genotype-
specific prevalence and distribution of human papillomavirus genotypes in underserved Latino
women with abnormal Papanicolaou tests. J Am Soc Cytopathol 3:42-48.
31. de Jonge M, Busecke G, Heinecke A, Bettendorf O. 2013. Human papillomavirus genotype
distribution in cytologically screened women from northwest Germany. Acta Cytol. 57(6):591-598.
32. Vidal A, Murphy S, Hernandez B, Vasquez B, Bartlett J,Oneko O, et al. 2011. Distribution
of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women.
Infectious Agents and Cancer. 6:20.
33. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, et al. 2005. IARC
HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in
cytologically normal women in the International Agency for Research on Cancer HPV prevalence
surveys: a pooled analysis. Lancet. 366:991-998.
34. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. 2007. Worldwide
prevalence and genotype distribution of cervical human papillomavirus DNA in women with
normal cytology: a meta-analysis. Lancet Infect Dis.7:453-459.
35. Simonella LM, Lewis H, Smith M, Neal H, Bromhead C, Canfell K. 2013. Type-specific
oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. BMC
Infect Dis.13:114-123.
36. Arbyn M, Benoy I, Simoens C, Bogers J, Beutels P, Depuydt C. 2009. Prevaccination
distribution of human papillomavirus types in women attending at cervical cancer screening in
Belgium. Cancer Epidemiol Biomarkers Prev.18:321-230.
37. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. 2012. Potential impact
of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer.
7:38-48.
38. Aedo S, Melo A, García P, Guzmán P, Capurro I, Roa JC. 2007. Detección y tipificación
de virus papiloma humano en lesiones preneoplásicas del cuello uterino mediante PCR-RFLP. Rev
Méd Chile. 135:167-173.
39. Derchain SF, Rabelo-Santos SH, Sarian LO, Zeferino LC, de Oliveira Zambeli ER, do
Amaral Westin MC, et al. Human papillomavirus DNA detection and histological findings in
women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol